岳健, 马飞, 张灵小, 李俏, 樊英, 王佳玉, 李青, 张频, 徐兵河. 卡培他滨联合多西他赛或长春瑞滨治疗乳腺癌肝转移的临床观察及疗效分析[J]. 中国肿瘤临床, 2013, 40(21): 1304-1308. DOI: 10.3969/j.issn.1000-8179.20131441
引用本文: 岳健, 马飞, 张灵小, 李俏, 樊英, 王佳玉, 李青, 张频, 徐兵河. 卡培他滨联合多西他赛或长春瑞滨治疗乳腺癌肝转移的临床观察及疗效分析[J]. 中国肿瘤临床, 2013, 40(21): 1304-1308. DOI: 10.3969/j.issn.1000-8179.20131441
shu
Jian YUE, Fei MA, Lingxiao ZHANG, Qiao LI, Ying FAN, Jiayu WANG, Qing LI, Ping ZHANG, Binghe XU. Clinical observations and outcomes of capecitabine-based regimens in treating Chinese patients with liver metastases from breast cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 40(21): 1304-1308. DOI: 10.3969/j.issn.1000-8179.20131441
Citation: Jian YUE, Fei MA, Lingxiao ZHANG, Qiao LI, Ying FAN, Jiayu WANG, Qing LI, Ping ZHANG, Binghe XU. Clinical observations and outcomes of capecitabine-based regimens in treating Chinese patients with liver metastases from breast cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 40(21): 1304-1308. DOI: 10.3969/j.issn.1000-8179.20131441
shu

卡培他滨联合多西他赛或长春瑞滨治疗乳腺癌肝转移的临床观察及疗效分析

Clinical observations and outcomes of capecitabine-based regimens in treating Chinese patients with liver metastases from breast cancer

    摘要
  • 摘要:
      目的  探讨含卡培他滨不同化疗方案治疗乳腺癌肝转移的疗效及不良反应。
      方法  收集2000年1月至2011年12月中国医学科学院肿瘤医院收治的163例使用多西他赛/卡培他滨或长春瑞滨/卡培他滨治疗的乳腺癌肝转移患者，回顾性分析临床特点，探讨两种方案的不良反应及疗效。
      结果  全组共纳入163例患者，接受多西他赛/卡培他滨治疗109例（66.9%），长春瑞滨/卡培他滨组54例（33.1%）。多西他赛/卡培他滨组可评价疗效病例中CR 4例、PR 55例、SD 25例、PD 22例，不详3例，客观有效率为54.1%（59/109），临床获益率77.1%（84/109）；长春瑞滨/卡培他滨组可评价疗效病例中CR 1例、PR 26例、SD 11例、PD 13例，不详3例，客观有效率为50.0%（27/54），临床获益率为70.4%（38/54）。在3~4级血液学不良反应方面长春瑞滨/卡培他滨组发生率为42.6%（23/54），3~4级非血液学不良反应主要表现为手足综合征1例（18.9%）、胃肠道反应2例（3.8%），均高于多西他赛/卡培他滨治疗组。多西他赛/卡培他滨中位无疾病进展时间（progression free survival，PFS）为8个月，中位肝转移后生存（overall survival after liver metastases，LMS）为26个月，中位转移后生存（post metastasis survival，MSR）为30个月；长春瑞滨/卡培他滨组中位PFS为6个月，中位LMS为20个月，中位MSR为28个月。多西他赛联合卡培他滨方案在PFS、LMS以及MSR均较长春瑞滨联合卡培他滨方案延长，但无显著性差异。
      结论  含卡培他滨化疗方案应用乳腺癌肝转移治疗耐受性良好，其中多西他赛/卡培他滨方案在疗效和耐受性方面可能优于长春瑞滨/卡培他滨方案。

     

    Abstract:
      Objective  To evaluate the efficacy and safety of capecitabine-based regimens in treating patients with liver metastases from breast cancer.
      Methods  A total of 163 patients with liver metastases from breast cancer who received capecitabine-based regimens between January 1, 2000 and Dec 31, 2011 were retrospectively reviewed. The clinicopathological characteristics and treatment outcomes of these patients were evaluated.
      Results  Of the 163 patients retrospectively analyzed, 109 received docetaxel plus capecitabine (TX) and 54 received vinorelbine plus capecitabine (NX). TX treatment achieved objective responses in 59 patients (54.1%), including complete response in four patients, partial response in 55 patients, and stable disease in 25 patients. In patients who received NX, the objective response and clinical benefit rates were 50.0% and 70.4%, respectively; one patient had a complete response, 26 patients had a partial response, and 11 patients had a stable disease. The safety profiles of TX treatment were more favorable and predictable compared with NX treatment, with a low incidence of grade 3/4 adverse events in hematological and non-hematological toxicities. Results showed that median overall survival after liver metastases (LMS), progression-free survival (PFS), and post-metastasis survival (MSR) were 26, 8, and 28 months in the TX arm. LMS, PFS, and MSR were longer in the TX arm than in the NX arm.
      Conclusion  Capecitabine-based regimens showed tolerance in patients with liver metastases from breast cancer. TX treatment had a tendency of lower toxicity and was more effective compared with NX treatment.

     

    • HTML全文
    • 参考文献(19)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回